Chemistry:Avacincaptad pegol
From HandWiki
Short description: Medication
| Clinical data | |
|---|---|
| Trade names | Izervay |
| Other names | Zimura |
| License data | |
| Routes of administration | Intravitreal |
| Drug class | Complement inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C395H453F21N142Na39O262P39 |
| Molar mass | 13885.245 g·mol−1 |
Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration.[1] Avacincaptad pegol is a complement inhibitor.[1]
Avacincaptad pegol was approved for medical use in the United States in August 2023.[2][3][4]
Medical uses
Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.[5]
Society and culture
Avacincaptad pegol is the international nonproprietary name.[6]
References
- ↑ 1.0 1.1 1.2 "Izervay- avacincaptad pegol injection". 9 August 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1642fe6a-dc26-4d20-ae6e-654af744e3bd.
- ↑ "Novel Drug Approvals for 2023". 18 August 2023. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023.
This article incorporates text from this source, which is in the public domain.
- ↑ "Iveric Bio Receives U.S. FDA Approval for Izervay (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy" (Press release). Astellas Pharma Inc. 4 August 2023. Archived from the original on 26 August 2023. Retrieved 25 August 2023 – via PR Newswire.
- ↑ "Avacincaptad Pegol: First Approval". Drugs 83 (15): 1447–1453. October 2023. doi:10.1007/s40265-023-01948-8. PMID 37814173. https://figshare.com/articles/online_resource/Avacincaptad_Pegol_First_Approval/24123651. Retrieved 18 December 2023.
- ↑ "Drug Approval Package: Izervay". 1 September 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217225Orig1s000TOC.cfm.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information 30 (1). 2016.
External links
- Clinical trial number NCT02686658 for "Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration" at ClinicalTrials.gov
- Clinical trial number NCT04435366 for "A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)" at ClinicalTrials.gov
 |  |
